HCC patients who initially responded but ultimately progressed on BLU-554 treatment were reported to harbor gatekeeper and hinge-1 mutations in the tyrosine kinase domain of FGFR4, which may disturb the binding of BLU-554 57. Here, FGFR4 is linked to hepatocellular carcinoma.